DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) is a leading pharmaceutical retail chain operator in China that manufactures, wholesales, and retails a wide range of pharmaceutical and healthcare products, including Chinese and Western patent medicines; ginseng and antler tonic medicinal materials; Chinese herbal pieces; health care products; medical equipment; antibiotics; biochemicals; biologics (excluding vaccines); health foods; nursing supplies; and other commodities such as proprietary Chinese medicines, chemical preparations, and generic and branded drugs. Founded in 1999 and headquartered at No. 410-1, Longxi Avenue, Liwan District, Guangzhou, Guangdong Province, the company employs over 43,000 full-time staff and maintains an extensive chain network across China, with nationwide operations encompassing self-built stores, mergers and acquisitions, franchises, and entry into new markets including Shanghai and Inner Mongolia. In recent developments, DaShenLin has aggressively expanded its store footprint, achieving a net increase of 2,479 stores in 2024 (including 907 self-built, 420 via mergers and acquisitions, and 1,885 franchises, net of closures) and 69 stores in the first quarter of 2025, alongside ongoing store optimization efforts that improve quality, efficiency, and gross margins through refined product portfolios, supply chain integration, and procurement cost reductions; the company also completed an equity buyback of 6.7 million shares (0.59% of capital) for CNY 100.72 million in 2024 and reported revenue of CNY 26.5 billion with net profit of CNY 915 million for 2024, followed by strong first-three-quarters 2025 performance including CNY 20.1 billion in revenue and CNY 1.08 billion in net profit.